

Amneal Pharmaceuticals, Inc. (AMRX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001723128

Amneal Pharmaceuticals, Inc. AMRX; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 48.4; sampling error 2.5 points; lower is stronger
Rank	180 of 371
Profitability	B percentile 35.9
Solvency	D percentile 75.7
Growth and financing	B percentile 30.5
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$3.7B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	11 of 14
Graded from	filings received through Feb 27, 2026 224 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$19.65 2026-10-08; market equity \$6.3B
Price used in grade	None

C, the tortoise
middle fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it

Rescans on file: E from Mar 21, 2022, E from Mar 21, 2024, D from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

Amneal Pharmaceuticals, Inc. (the "Company", "we," "us," or "our") is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of

pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States ("U.S."), India, and Ireland.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 35.9						
Gross profitability		30.3%	32.2%	49.3	372	2025-12-31
Return on invested capital		16.5%	9.3%	28.8	74	2025-12-31
Accruals ratio		(7.5%)	(6.6%)	52.2	811	2025-12-31
Gross margin stability, five years		1.0 pts	2.8 pts	13.2	243	2025-12-31
Solvency, sleeve percentile 75.7						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	(0.31)			required facts have no common fiscal period end
Net debt to EBITDA		5.07x	1.82x	82.4	75	2025-12-31
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		2.17x	2.96x	69.0	839	2025-12-31
Growth and financing, sleeve percentile 30.5						
Revenue growth, three-year compound		10.9%	10.0%	47.8	415	2025-12-31
Free cash flow growth, three-year compound		143.5%	10.9%	2.1	96	2025-12-31
Reinvestment rate		161.3%	37.1%	19.4	104	2025-12-31
Asset growth, three years		(1.1%)	2.1%	53.6	704	2025-12-31
Net share issuance, one year		1.5%	2.5%	29.4	634	2026-02-13

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
175	ClearPoint Neuro, Inc. (CLPT)	47.0	C	
176	Anika Therapeutics, Inc. (ANIK)	47.3	C	fortress balance sheet
177	Davita Inc. (DVA)	47.6	C	
178	Kymera Therapeutics, Inc. (KYMR)	47.8	C	dilution
179	Scynexis Inc. (SCYX)	48.1	C	fortress balance sheet

180	Amneal Pharmaceuticals, Inc. (AMRX) <	48.4	C
181	Macrogenics Inc. (MGNX)	48.6	C
182	Savara Inc. (SVRA)	48.9	C short runway, fortress balance sheet
183	Biodesix Inc. (BDSX)	49.2	C dilution
184	Evolus, Inc. (EOLS)	49.5	C
185	Neogen Corp. (NEOG)	49.7	C late filer

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	74.5%	8.0%	84
Distance from 52-week high	(4.1%)	(31.4%)	94
EBIT to enterprise value	4.5%	(1.5%)	74
Free cash flow yield	4.3%	(1.0%)	77
Book value to price	0.01	0.28	12
Sales to price	0.48	0.31	65
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.34	(0.14)	84

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$127.6M
Operating cash flow, four quarters	\$200.8M
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$36.8M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$1.1B	2025-12-31	2026-02-27	10-K	0001723128-26-000011
2	assets	us-gaap:Assets	\$3.7B	2025-12-31	2026-02-27	10-K	0001723128-26-000011
3	operating income	us-gaap:OperatingIncomeLoss	\$394.1M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNondeductible	\$189.2M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$11.3M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
6	total debt	us-gaap:LongTermDebt	\$2.6B	2025-12-31	2026-02-27	10-K	0001723128-26-000011
7	book equity	us-gaap:StockholdersEquity	-\$70.8M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$282.0M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
9	total debt	us-gaap:LongTermDebt	\$2.4B	2024-12-31	2026-02-27	10-K	0001723128-26-000011
10	book equity	us-gaap:StockholdersEquity	-\$109.3M	2024-12-31	2026-02-27	10-K	0001723128-26-000011
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$110.6M	2024-12-31	2026-02-27	10-K	0001723128-26-000011
12	net income	us-gaap:NetIncomeLoss	\$72.1M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$340.0M	2025-12-31	2026-02-27	10-K	0001723128-26-000011

14	assets	us-gaap:Assets	\$3.5B	2024-12-31	2026-02-27	10-K	0001723128-26-000011
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.0B	2025-12-31	2026-02-27	10-K	0001723128-26-000011
16	gross profit	us-gaap:GrossProfit	\$1.0B	2024-12-31	2026-02-27	10-K	0001723128-26-000011
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.8B	2024-12-31	2026-02-27	10-K	0001723128-26-000011
18	gross profit	us-gaap:GrossProfit	\$820.6M	2023-12-31	2026-02-27	10-K	0001723128-26-000011
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.4B	2023-12-31	2026-02-27	10-K	0001723128-26-000011
20	gross profit	us-gaap:GrossProfit	\$784.7M	2022-12-31	2025-02-28	10-K	0001723128-25-000012
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.2B	2022-12-31	2025-02-28	10-K	0001723128-25-000012
22	gross profit	us-gaap:GrossProfit	\$769.0M	2021-12-31	2024-03-14	10-K	0001723128-24-000014
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.1B	2021-12-31	2024-03-14	10-K	0001723128-24-000014
24	depreciation amortization	us-gaap:Depreciation	\$57.3M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
25	current assets	us-gaap:AssetsCurrent	\$1.9B	2025-12-31	2026-02-27	10-K	0001723128-26-000011
26	current liabilities	us-gaap:LiabilitiesCurrent	\$881.6M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$70.1M	2025-12-31	2026-02-27	10-K	0001723128-26-000011
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$295.1M	2024-12-31	2026-02-27	10-K	0001723128-26-000011
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$51.9M	2024-12-31	2026-02-27	10-K	0001723128-26-000011
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$345.6M	2023-12-31	2026-02-27	10-K	0001723128-26-000011
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$43.2M	2023-12-31	2026-02-27	10-K	0001723128-26-000011
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$65.1M	2022-12-31	2025-02-28	10-K	0001723128-25-000012
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$46.4M	2022-12-31	2025-02-28	10-K	0001723128-25-000012
34	current assets	us-gaap:AssetsCurrent	\$1.6B	2024-12-31	2026-02-27	10-K	0001723128-26-000011
35	current liabilities	us-gaap:LiabilitiesCurrent	\$1.1B	2024-12-31	2026-02-27	10-K	0001723128-26-000011
36	assets	us-gaap:Assets	\$3.5B	2023-12-31	2025-02-28	10-K	0001723128-25-000012
37	assets	us-gaap:Assets	\$3.8B	2022-12-31	2024-03-14	10-K	0001723128-24-000014
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	314,629,101	2026-02-13	2026-02-27	10-K	0001723128-26-000011
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	309,966,341	2025-02-14	2025-02-28	10-K	0001723128-25-000012